ST3GAL1

Across TCGA pan-cancer cohorts, ST3GAL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ST3GAL1 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ST3GAL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ST3GAL1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where ST3GAL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.296	1.000	.011	22	view →
PDAC	OS	Median	III,IV	0.285	0.787	.003	16	view →
CCRCC	OS	Median	III,IV	0.104	0.989	.010	14	view →
LSCC	OS	Median	All	0.731	0.861	.034	3	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.357	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ST3GAL1–HNSC (OS)

Open the HNSC breakdown →